Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in Adult MDD
NCT00668525Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Apr 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Escitalopram oxalate oral solution in major depressive disorder (MDD) (3 arms), sponsored by Forest Laboratories. Primary endpoint: Montgomery Asberg Depression Rating Scale at 8 weeks. Started Apr 2008; status: completed.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00668525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668525.